Association between body mass index, lipid profiles, and types of urinary stones

Renal Failure

Volumn 34, Issue 9, 2012, Pages 1140-1143

  Inci, Mehmet ^a   Demirtas, Abdullah ^b   Sarli, Bahadir ^c   Akinsal, Emrecan ^b   Baydilli, Numan ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

^c Education Hospital   (Turkey)

Author keywords

Body mass index; Hypercholesterolemia; Hypertriglyceridemia; Nephrolithiasis

Indexed keywords

CALCIUM PHOSPHATE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; WEDDELLITE; WHEWELLITE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFRARED SPECTROSCOPY; MALE; PRIORITY JOURNAL; STONE FORMATION; UROLITHIASIS;

ADULT; BODY MASS INDEX; CALCIUM OXALATE; CALCIUM PHOSPHATES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RETROSPECTIVE STUDIES; URINARY CALCULI;

EID: 84866409840     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.713298     Document Type: Article

References (42)

1. Pak CY. Kidney stones. Lancet. 1998;351:1797-1801.
2. Saigal CS, Joyce G, Timilsina AR. Direct and indirect costs of nephrolithiasis in an employed population: Opportunity for disease management? Kidney Int. 2005;68:1808-1814.
3. Daudon M, Jungers P. Drug-induced renal calculi: Epidemiology, prevention and management. Drugs. 2004;64: 245-275.
4. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Aprospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 1993;328:833-838.
5. Kaul P, Sidhu H, Sharma SK, Nath R. Calculogenic potential of galactose and fructose in relation to urinary excretion of lithogenic substances in vitamin B6 deficient and control rats. J Am Coll Nutr. 1996;15:295-302.
6. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 2001;59: 270-276.
7. Saldana TM, Basso O, Darden R, Sandler DP. Carbonated beverages and chronic kidney disease. Epidemiology. 2007;18: 501-506.
8. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol. 2011;8:483-494.
9. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2011;12(Fall):e157-e180.
10. Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney Int. 2009;75:585-595.
11. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. J Am Med Assoc. 2002;288:1723-1727.
12. Kopelman PG. Obesity as a medical problem. Nature. 2000;404: 635-643.
13. Hamano S, Nakatsu H, Suzuki N, Tomioka S, Tanaka M, Murakami S. Kidney stone disease and risk factors for coronary heart disease. Int J Urol. 2005;12:859-863.
14. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. J Am Med Assoc. 2005;293:455-462.
15. Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ. Body size and risk of kidney stones. J Am Soc Nephrol. 1998;9: 1645-1652.
16. Sakhaee K, Adams-Huet B, Moe OW, Pak CY. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002;62:971-979.
17. Cameron MA, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K. Urine composition in type 2 diabetes: Predisposition to uric acid nephrolithiasis. J Am Soc Nephrol. 2006;17:1422-1428.
18. Pak CY, Sakhaee K, Moe O, et al. Biochemical profile of stoneforming patients with diabetes mellitus. Urology. 2003;61: 523-527.
19. Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68:1230-1235.
20. Domingos F, Serra A. Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. Nephrol Dial Transplant. 2011;26:864-868.
21. Rendina D, Mossetti G, De Filippo G, et al. Association between metabolic syndrome and nephrolithiasis in an inpatient population in southern Italy: Role of gender, hypertension and abdominal obesity. Nephrol Dial Transplant. 2009;24:900-906.
22. Cappuccio FP, Siani A, Barba G, et al. A prospective study of hypertension and the incidence of kidney stones in men. J Hypertens. 1999;17:1017-1022.
23. Obligado SH, Goldfarb DS. The association of nephrolithiasis with hypertension and obesity: A review. Am J Hypertens. 2008;21:257-264.
24. Diagnosis and classification of diabetes mellitus. Diabetes Care. 34(Suppl. 1):S62-S69.
25. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42: 1206-1252.
26. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
27. Dretler SP. Ureteral stone disease. Options for management. Urol Clin North Am. 1990;17:217-230.
28. Smith CL. Renal stone analysis: Is there any clinical value? Curr Opin Nephrol Hypertens. 1998;7:703-709.
29. Daudon M, Jungers P. Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Nephron Physiol. 2004;98:31-36.
30. Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med. 1989;111:1006-1009.
31. Li WM, Chou YH, Li CC, et al. Association of body mass index and urine pH in patients with urolithiasis. Urol Res. 2009;37: 193-196.
32. Ekeruo WO, Tan YH, Young MD, et al. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol. 2004;172:159-163.
33. Taylor EN, Curhan GC. Body size and 24-hour urine composition. Am J Kidney Dis. 2006;48:905-915.
34. Siener R, Glatz S, Nicolay C, Hesse A. The role of overweight and obesity in calcium oxalate stone formation. Obes Res. 2004;12:106-113.
35. Taylor EN, Mount DB, Forman JP, Curhan GC. Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors. Am J Kidney Dis. 2006;47: 780-789.
36. Grases F, Sanchis P, Perello J, Costa-Bauza A. Role of uric acid in different types of calcium oxalate renal calculi. Int J Urol. 2006;13:252-256.
37. Grover PK, Ryall RL. Critical appraisal of salting-out and its implications for chemical and biological sciences. Chem Rev. 2005;105:1-10.
38. Sakhaee K, Maalouf NM. Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol. 2008;28:174-180.
39. Chou YH, Su CM, Li CC, et al. Difference in urinary stone components between obese and non-obese patients. Urol Res. 2010;39:283-287.
40. Kajikawa H. The influence of dietary lipids on nephrolithiasis in rats. Nippon Hinyokika Gakkai Zasshi. 1998;89:931-938.
41. Tsujihata M, Momohara C, Yoshioka I, Tsujimura A, Nonomura N, Okuyama A. Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol. 2008;180: 2212-2217.
42. Iba A, Kohjimoto Y, Mori T, et al. Insulin resistance increases the risk of urinary stone formation in a rat model of metabolic syndrome. BJU Int. 2010;106:1550-1554.